Prestige Consumer Healthcare (NYSE:PBH) Issues FY 2025 Earnings Guidance

Prestige Consumer Healthcare (NYSE:PBH) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share (EPS) guidance of 4.500-4.500 for the period, compared to the consensus estimate of 4.440. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Analysts Set New Price Targets

A number of analysts have issued reports on PBH shares. DA Davidson reissued a “buy” rating and issued a $95.00 price objective on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Raymond James raised Prestige Consumer Healthcare to a “moderate buy” rating in a research report on Thursday, December 19th. Sidoti lowered Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective on the stock. in a research note on Monday, December 9th. Finally, StockNews.com raised Prestige Consumer Healthcare from a “hold” rating to a “buy” rating in a report on Friday, January 24th. Two analysts have rated the stock with a hold rating and three have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH stock opened at $75.90 on Thursday. The business has a fifty day simple moving average of $79.29 and a 200 day simple moving average of $75.25. The company has a market cap of $3.75 billion, a P/E ratio of 18.47, a P/E/G ratio of 2.15 and a beta of 0.50. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. Prestige Consumer Healthcare has a twelve month low of $60.00 and a twelve month high of $86.36.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings results on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. On average, sell-side analysts forecast that Prestige Consumer Healthcare will post 4.46 EPS for the current fiscal year.

Insider Transactions at Prestige Consumer Healthcare

In other news, EVP Adel Mekhail sold 9,063 shares of the stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $82.00, for a total value of $743,166.00. Following the completion of the sale, the executive vice president now owns 18,365 shares of the company’s stock, valued at approximately $1,505,930. This represents a 33.04 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares in the company, valued at approximately $1,641,747.30. This represents a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,810 shares of company stock worth $3,187,300. Insiders own 1.60% of the company’s stock.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.